A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma

Abstract excerpt

BACKGROUND: Medulloblastoma (MB) is one of the most frequent malignant brain tumors of children, and a large set of these tumors is characterized by aberrant activation of the sonic hedgehog (SHH) pathway. While some tumors initially respond to inhibition of the SHH pathway component Smoothened (SMO), tumors ultimately recur due to downstream resistance mechanisms, indicating a need for novel therapeutic options....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Glioma Diagnosis and Treatment
• Share to Hedgehog Signaling Pathway Studies
• Share to Histone Deacetylase Inhibitors Research